One of our favorite biotech stocks, Inovio Pharmaceuticals Inc. (Nasdaq: INO), has seen a steep fall lately. Inovio stock is down 20.5% since it reached a 2015 high of $10.77 on April 22. Even with this recent slip, INO is still one of our …
Inovio's shares have underperformed the industry so far this year. The stock has lost 16.9% versus the industry's increase of 3.9% during the period. Inovio's earnings performance is a mixed bag. The company surpassed expectations in two …
NASDAQ1mon
Inovio's shares, by contrast, appear to have simply followed the broader biotech industry lower last month, evinced by the poor performance of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) in October. Inovio took a particularly hard …
Interested in a cure for cancer? HIV? Hepatitis B? Influenza? Inovio Pharmaceuticals Inc (NASDAQ:INO) has taken that hope on step further. It’s working on vaccines for all these. And it’s getting pretty impressive results. So much so that …
Investors lapped up the news. Both stocks have popped this week, adding to solid gains for the year. Inovio (INO) stock is up nearly 70% so far in 2016. And shares of GeneOne Life Science are up 50% on the Seoul stock exchange. But …
or as an investor interested in possibly purchasing Inovio stock. Inovio Pharmaceuticals, by the numbers For the quarter, Inovio generated $5.17 million in revenue, which was comprised of $4.25 million in collaborative arrangements, $0.11 …
Shares of Inovio Pharmaceuticals Inc closed the previous trading session at 7.88 down -0.11 -1.38% with 1,631,705 …
Inovio Pharmaceuticals Inc. INO shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study PENNVAX-GP is a combination of four HIV antigens designed …
According to S&P; Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit decline wasn't the result of a negative clinical …